SCHEMBL451255

SCHEMBL451255

COc1ccc(-n2c(C(C)Cl)nc3ccccc3c2=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
LMNA P02545 2/20 0.62
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
RAB9A P51151 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
MAPT P10636 1/20 0.56
PDE10A Q9Y233 4/20 0.56
G6PD P11413 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
PTGS2 P35354 1/20 0.55
TSHR P16473 1/20 0.55
CXCR3 P49682 1/20 0.53
KCNH2 Q12809 1/20 0.53
HRH3 Q9Y5N1 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16346178 0.88 ALDH1A1 (0.53) ALDH1A1LMNARAB9AMAPTSMN1; SMN2
SCHEMBL448044 0.86 SMN1; SMN2 (0.60) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL452172 0.85 ALDH1A1 (0.61) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL450719 0.85 PTGS2 (0.51) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL4579481 0.83 ALDH1A1 (0.59) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL29154649 0.80 ALDH1A1 (0.76) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL451745 0.79 CXCR3 (0.55) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL449210 0.79 CXCR3 (0.59) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL29175100 0.79 ALDH1A1 (0.70) ALDH1A1LMNAMEN1KMT2ARAB9A
SCHEMBL9672724 0.79 ALDH1A1 (0.70) ALDH1A1LMNAMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
EP-1521746-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2005-04-13 EP disclosed
WO-2003076418-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885LMNA 3754/4885MEN1 4424/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885LMNA 3754/4885MEN1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.